KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulgent Genetics (FLGT) Total Liabilities (2016 - 2025)

Fulgent Genetics' Total Liabilities history spans 10 years, with the latest figure at $106.8 million for Q4 2025.

  • For Q4 2025, Total Liabilities rose 17.63% year-over-year to $106.8 million; the TTM value through Dec 2025 reached $106.8 million, up 17.63%, while the annual FY2025 figure was $106.8 million, 17.63% up from the prior year.
  • Total Liabilities for Q4 2025 was $106.8 million at Fulgent Genetics, up from $93.8 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $197.5 million in Q1 2021 and bottomed at $83.0 million in Q1 2025.
  • The 5-year median for Total Liabilities is $105.1 million (2024), against an average of $115.5 million.
  • The largest annual shift saw Total Liabilities surged 2383.55% in 2021 before it plummeted 39.54% in 2023.
  • A 5-year view of Total Liabilities shows it stood at $112.8 million in 2021, then increased by 2.96% to $116.2 million in 2022, then dropped by 12.17% to $102.0 million in 2023, then dropped by 11.01% to $90.8 million in 2024, then rose by 17.63% to $106.8 million in 2025.
  • Per Business Quant, the three most recent readings for FLGT's Total Liabilities are $106.8 million (Q4 2025), $93.8 million (Q3 2025), and $88.2 million (Q2 2025).